Global Information, Inc.
¤é°ÓÀô²y°T®§¦³­­¤½¥q
ºô¯¸¾ÉÄý
²£·~/¥«³õ¤ÀÃþ
¦³¿³½ì°Ñ»P¥þ²y°ê»Ú·|ij(®i¥Ü·|)¶Ü?

»sÃÄ ²£·~/¥«³õ±¡³ø¸ê®Æ

Market Research on Pharmaceutical

1 2 3 4 5 6 7 8 9 10 ¤U¤@­¶ >>

Á{§ÉÀËÅçªA°È¥«³õ¡]¦¨ªø¾÷·|¡BÄvª§¤ÀªR¡BÄvª§¥ø·~ÀÉ®×¸ê®Æ¡^
The Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 112093

¤U¤@­Ó¬Ì­]¡H2010¡ã2020¦~ªº²£«~½u¤W¤§HIV¡BºÄ¯e¡B¨g¤ü¯f¡BMRSA¥H¤Î¨ä¥L30ºØ¥H¤Wªº¬Ì­]¥Ø¼Ð
What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and 30 Other Vaccine Targets in the 2010-2020 Pipeline
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 112092

§Ü¯f¬rÀøªk¡G§Þ³N¡B¥«³õ¡B¥ø·~
Antiviral Therapeutics - technologies, markets and companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70939

¤ß¦åºÞ¤§ÃĪ«¿é°e¡G§Þ³N¡B¥«³õ¡B¥ø·~
Cardiovascular Drug Delivery - technologies,markets and companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70936

¤¤¼Ï¯«¸g¨t²Î¬ÛÃö¤§ÃĪ«¶Ç¿é¡G§Þ³N・¥«³õ・¥ø·~
Drug Delivery in Central Nervous System Diseases - technologies, markets and companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70934

°ò¦]ªvÀø¡G§Þ³N¡B¥«³õ¡B¥ø·~
Gene Therapy - technologies, markets and companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70931

Àù¯g¬ÛÃö¤§ÃĪ«¶Ç¿é¡G§Þ³N¡B¥«³õ¡B¥ø·~
Drug Delivery in Cancer - technologies, markets and companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70928

ªü¯÷®üÀq¯g¡G·sÃÄ・¥«³õ・¥ø·~
Alzheimer disease - new drugs, markets and companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70927

¤@®ñ¤Æ´á¡GªvÀø・¥«³õ・¥ø·~
Nitric Oxide - Therapeutics, Markets and Companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70925

­Ó§O¤ÆÂåÀø¡G¬ì¾Çªº・°Ó·~ªº±¡¶Õ
Personalized Medicine - scientific & commercial aspects
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70924

¯kµhªvÀø¡GÂåÀøÃÄ«~・¥«³õ・¥ø·~
Pain Therapeutics - Drugs, Markets and Companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70923

°Êª«¥Íª«¬ì§Þ¡G§Þ³N・¥«³õ・¥ø·~
Animal Biotechnology - Technologies, Markets and Companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70922

¸g¥ÖÃĪ«µ¹ÃÄ¡G§Þ³N・¥«³õ・¥ø·~
Transdermal Drug Delivery - Technologies, Markets, and Companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70921

¯«¸g«OÅ@¡GÂåÀøÃÄ«~・¥«³õ・¥ø·~
Neuroprotection - Drugs, Markets and Companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70919

²Ó­MªvÀø:§Þ³N£»¥«³õ£»¥ø·~
Cell Therapy - Technologies, Markets and Companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70916

¤À¤l¶EÂ_¡R§Þ³N£»¥«³õ£»¥ø·~
Molecular Diagnostics - Technologies, Markets and Companies
¥Xª©¤é´Á : 2010/02
°Ó«~½s½X : 70915

Alcon Inc.¡G»sÃÄ¥ø·~²¤¶
Alcon Inc.: PharmaVitae Profile
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111677

¤ß¦åºÞ»P¥NÁÂ¥«³õ­²·sªº¶}µo¿é°eºÞ¹D
Commercial Insight: Cardiovascular and metabolic market overview Innovative development pipeline provides limited growth as primary care markets become generic
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111674

²Ä2«¬¿}§¿¯f¡GªvÀøÃĺ޹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Type-2 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111662

²Ä1«¬¿}§¿¯f¡GªvÀøÃĺ޹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Type 1 Diabetes - Drug Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111661

Ãö¸`­·Àã¡GªvÀøÃĺ޹D¤ÀªR¤Î¨ì2015¦~¬°¤îªº¥«³õ¹w´ú
Rheumatoid Arthritis - Drug Pipeline Analysis and Market Forecasts to 2015
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111660

µÇŦÀù¡GªvÀøÃĪººÞ¹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Renal Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111659

«e¦C¸¢Àù¡GªvÀøÃĺ޹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Prostate Cancer - Drug Pipeline Analysis and Market Forecasts to 2015
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111658

§Z±_Àù¡GªvÀøÃĪººÞ¹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Ovarian Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111657

«D¦óªNª÷²O¤Ú½F¡GªvÀøÃĺ޹D¤ÀªR¤Î¨ì2015¦~¬°¤îªº¥«³õ¹w´ú
Non-Hodgkin's Lymphoma (NHL) - Drug Pipeline Analysis and Market Forecasts to 2015
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111656

¬y¦æ©Ê·P«_¬Ì­]¡GºÞ¹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Influenza Vaccines - Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111655

ÀYÀV³¡Àù¡GªvÀøÃĪººÞ¹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Head and Neck Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111653

µ²ª½¸zÀù(CRC)¡GªvÀøÃĺ޹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Colorectal Cancer (CRC) - Drug Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111651

¤l®cÀVÀù¡GªvÀøÃĺ޹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Cervical Cancer - Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111650

¹L±Ó©Ê¥Ö½§ª¢¡GªvÀøÃĪººÞ¹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Atopic Dermatitis - Drug Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111649

ªÎ­D¯g¡GªvÀøÃĪººÞ¹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Anti-Obesity - Drug Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111648

¯U¤ß¯g¡GªvÀøÃĺ޹D¤ÀªR¤Î¨ì2016¦~¬°¤îªº¥«³õ¹w´ú
Angina Pectoris - Drug Pipeline Analysis and Market Forecasts to 2016
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111647

»P¯f±w¤ä´©¹ÎÅé¨ó¤O¶i¦æ¥«³õ±Ð¨|
Collaborating with Patient Advocacy Groups to Educate the Marketplace
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111630

ºÞ²z·ÓÅU³¡ªù°w¹ï³B¤èÃľ¯¤§§Q¥Î«P¶i¡]pull-through¡^µ¦²¤
Developing Managed Care Pull-Through Excellence
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111629

¥H¯f±w¬°¤¤¤ß¡G»P¯f±w±µÄ²¡B«Ø¥ßÃö«Y¡B¤ä´©¤§­Ó®×¬ã¨s
Innovations in Patient-Focused Initiatives: Case Studies in Reaching, Engaging and Supporting Patients
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111625

ÂåÀø±Ð¨|­pµe°Ñ¥[ªÌ¶Ò¶°¤§³Ì¨Î®×¨Ò¬ã¨s
Best Practices in Recruitment for Medical Education Programs
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 111623

Àù¯gªvÀø¤§RNA¤zÂZªk¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
RNA Interference Therapy in Oncology Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109518

µÇŦÀùªvÀøÃĪ«¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Renal Cancer Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109080

Àù¯g¤§©ñ®g½uªvÀøÃĪ«¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Radiation Therapy in Oncology Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109079

³J¥Õ酶§í»s¾¯¦bÀù¯gªvÀøÃĪ«¤§¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109078

«e¦C¸¢ÀùªvÀøÃĪ«¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Prostate Cancer Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109077

Ð`肽¦bÀù¯gªvÀøÃĪ«¤§¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Peptides in Oncology Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109076

¯ØÅ¦ÀùªvÀøÃĪ«¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Pancreatic Cancer Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109075

¤W¥««á½Õ¬dÃĪ«¤£¨}¨Æ¥ó¤§³Ì¨Î®×¨Ò¬ã¨s¡G¬ü°ê¥«³õ
Best Practices for Post-Marketing Surveillance of Adverse Events within the U.S. 
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109074

§Z±_ÀùªvÀøÃÄ«~¥Í²£½u¡G2010¦~³Ì·sÁͶÕ
Ovarian Cancer Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109072

¯«¸g¤º¤Àªc¸~½F¤§²£«~½u¡G2010¦~³Ì·sÁͶÕ
Neuroendocrine Tumors Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109071

¶Â¦â¯À½FªvÀøÃĪ«¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Melanoma Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109070

Àù¯g°ò¦]ÀøªkÃĪ«¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Gene Therapy in Oncology Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109063

Àù¯g²Ó­M¿E¯ÀÀøªkÃĪ«¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Cytokine Therapy in Oncology Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109062

¤j¸zª½¸zÀùªvÀøÃĪ«¶}µo¶iµ{¡G2010¦~³Ì·s°Ê¦V
Colorectal Cancer Drug Pipeline Update 2010
¥Xª©¤é´Á : 2010/01
°Ó«~½s½X : 109061

1 2 3 4 5 6 7 8 9 10 ¤U¤@­¶ >>